What is the NOAEL for Benzylacetone?
Benzylacetone has 45 NOAEL studies in the database. The lowest reported value is 17.6 mg/m3 via inhalation in Human. Source: ToxValDB GESTIS DNEL.
NOAEL Data
REACH Registered
Cosmetic Ingredient
Benzylacetone
Also known as: 4-07-00-00713, BRN 1907123, EINECS 219-847-4, Methyl phenylethyl ketone, beta-Phenylethyl methyl ketone
CAS 2550-26-7
Benzylacetone (CAS 2550-26-7) is a chemical substance. Key regulatory status: REACH registered, 3 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, ECHA REACH.
Cross-Vertical Regulatory Divergence
Benzylacetone is prohibited in EU cosmetics but has active industrial GHS classifications.
SOURCE
Cross-vertical comparison
Cosmetics: ingredients.eu_status; Chemicals: ghs_classifications.signal_word
SOURCE
NOAEL studies
NOAEL studies
45
SOURCE
Chemical inventory jurisdictions
Regulatory lists
3
SOURCE
EU CLP Annex VI
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
11 fields
Name
Benzylacetone
CAS Number
2550-26-7
DTXSID
DTXSID6033241
Molecular Formula
C10H12O
InChI Key
AKGGYBADQZYZPD-UHFFFAOYSA-N
Monoisotopic Mass
148.088815
Synonyms
4-07-00-00713BRN 1907123EINECS 219-847-4Methyl phenylethyl ketonebeta-Phenylethyl methyl ketone
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
10 records
FragranceFlavouring and nutrient
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
3 records
| List | Keyword | Source |
|---|---|---|
| Europe | European Commission | Fl@vis |
| IFRA Transparency | IFRA | IFRA |
| consumer_product | P&G | Proctor & Gamble |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 45 of 45 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| =17.6 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB GESTIS DNEL |
| UZM5QH16YW | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| UZM5QH16YW | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| UZM5QH16YW | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| UZM5QH16YW | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| - | % | Incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 837 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 1240 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| 1350 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP ICE skin sensitization |
| =165 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =500 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =1000 | mg/kg bw/day | NOEL | oral | Rat | ECHA |
| 3 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 4 | unitless | Relative reliability score | Dermal | Human | NTP ICE skin sensitization |
| 137.1 | % | Viability (240 minutes) | Dermal | - | NTP ICE skin irritation |
| 143.4 | % | Viability (240 minutes) | Dermal | - | NTP ICE skin irritation |
| 149.9 | % | Viability (240 minutes) | Dermal | - | NTP ICE skin irritation |
| 66.1 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 87 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 89.9 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 92.3 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 96.5 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 99.2 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 101.9 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 102.3 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 103.2 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 103.3 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 118.7 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 133.2 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 134.7 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 150.3 | % | Viability (3 minutes) | Dermal | - | NTP ICE skin irritation |
| 72.4 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 74.1 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 77.6 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 78.4 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 81 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 86.6 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 88.1 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 91.9 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 93.5 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 100.4 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 104.6 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 141.2 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 142.2 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
| 151.3 | % | Viability (60 minutes) | Dermal | - | NTP ICE skin irritation |
Showing 45 of 45 studies
REACH Registration
Registration status from the ECHA REACH registered substances database.
SOURCE
ECHA
1 records
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 4-phenylbutan-2-one | 219-847-4 | ECHA overview → |
Australian Status (AICIS)
Australian industrial chemicals inventory status and applicable conditions.
SOURCE
AICIS inventory
1 records
Inventory Status
listed
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
prohibited
Max
-
Category
Fragrance
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
ChEMBL / DailyMed
BENZYLACETONE
ChEMBL Phase
Not listed
Adverse Events
0
Bioactivity
2
Cannabis Data
Same-CAS cannabis compliance and lab records where available.
SOURCE
Cannabis regulatory / lab data
efsa substances
1 cannabis record found in efsa substances.
View full cannabis profile →Frequently Asked Questions
What regulatory lists include Benzylacetone?
Benzylacetone appears on 3 regulatory/inventory lists including Europe, IFRA Transparency, consumer_product. Source: EPA CPDat.
Is Benzylacetone used in cosmetics?
Yes, Benzylacetone is also indexed as a cosmetic ingredient under the name Benzyl Acetone. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for Benzylacetone come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed, cannabis regulatory/lab databases. All data traces to primary regulatory sources and is updated from official government databases.
Does Benzylacetone have different safety status in cosmetics vs industrial chemicals?
Benzylacetone is prohibited in EU cosmetics but has active industrial GHS classifications.
Is Benzylacetone used outside industrial chemicals?
Benzylacetone also appears in cosmetics, pharmaceutical, cannabis databases.